ReviewHeart failure reviews2020
Heart failure with reduced and preserved ejection fraction in adult congenital heart disease.
Review in Heart failure reviews, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 34 citations in OpenAlex.
- Changes in pharmacotherapy in adults with Fontan circulation and associations with outcomes.International journal of cardiology. Congenital heart disease · 2026Article
- Single-Center Experience with Sacubitril/Valsartan in Patients with Congenital Heart Disease.Pediatric cardiology · 2026Article
- Clinical worsening in adult congenital heart disease and heart failure: A single-centre, observational study.International journal of cardiology. Congenital heart disease · 2026Article
- Valvular Heart Disease in Heart Failure with Preserved Ejection Fraction.Cardiac failure review · 2026Review
- Safety and Efficacy of GLP-1 Agonists in a Cohort of Patients with Fontan Circulation.Pediatric cardiology · 2025Article
- Risk of atherosclerotic cardiovascular disease after cancer diagnosis: findings from 3 prospective cohort studies.Journal of the National Cancer Institute · 2025Article
- Intraventricular pressure difference estimation based on blood speckle tracking-invasive validation and early clinical application.European heart journal. Cardiovascular Imaging · 2025Article
- Staged definitive repair for pulmonary atresia and ventricular septal defect 40 years after palliative surgery: a case report.General thoracic and cardiovascular surgery cases · 2023Article
- Born to Age: When Adult Congenital Heart Disease Converges With Geroscience.JACC. Advances · 2022Review
- Diastolic Dysfunction With Preserved Ejection Fraction After the Fontan Procedure.Journal of the American Heart Association · 2022Article
- SOX7 loss-of-function variation as a cause of familial congenital heart disease.American journal of translational research · 2022Article
- Antenatal and Perioperative Mechanisms of Global Neurological Injury in Congenital Heart Disease.Pediatric cardiology · 2021Review
- Application of B-Type Natriuretic Peptide in Neonatal Diseases.Frontiers in pediatrics · 2021Review
- The success and failure of the adult congenital heart.Heart failure reviews · 2020Article
- Echocardiography in Simple Congenital Heart Diseases: Guiding Adult Patient Management.Journal of cardiovascular echographyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart failure with reduced ejection fraction (HFrEF) is common in patients with adult congenital heart disease. Many of the most common congenital defects have a high prevalence of HFrEF, including left-sided obstructive lesions (aortic stenosis, coarctation of the aorta, Shone complex), tetralogy of Fallot, Ebstein anomaly, lesions in which there is a systemic right ventricle, and lesions palliated with a Fontan circulation. However, heart failure with preserved ejection fraction (HFpEF) is also prevalent in all these lesions. Comprehensive evaluation includes physical exam, biomarkers, echocardiography and advanced imaging, exercise stress testing, and, in some cases, invasive hemodynamics. Guideline-directed medical therapy for HFrEF can be applied to left-sided lesions and may be considered on an individual basis for systemic right ventricle and single-ventricle patients. Medical therapy is limited for HFpEF. However, in both HFrEF and HFpEF, ventricular dyssynchrony and arrhythmias play an important role, and medications for rhythm control, ablation, and cardiac resynchronization therapy should be considered. Finally, aggressive management of cardiovascular risk factors and comorbidities, including, but not limited to, hypertension, obesity, diabetes, dyslipidemia, and obstructive sleep apnea, cannot be overemphasized.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.